This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Bone Metastasis Overview
- Therapeutics Development
- Pipeline Products for Bone Metastasis - Overview
- Pipeline Products for Bone Metastasis - Comparative Analysis
- Bone Metastasis - Therapeutics under Development by Companies
- Bone Metastasis - Therapeutics under Investigation by Universities/Institutes
- Bone Metastasis Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Bone Metastasis - Products under Development by Companies
- Bone Metastasis - Products under Investigation by Universities/Institutes
- Bone Metastasis - Companies Involved in Therapeutics Development
- Ablynx NV
- Alethia Biotherapeutics Inc.
- Amgen Inc.
- Amura Holdings Limited
- Bayer AG
- Campus Technologies Freiburg GmbH
- ChemoCentryx, Inc.
- Deciphera Pharmaceuticals, LLC
- Oncobiologics, Inc.
- Oncodrone BV
- Osteologix Holdings Plc
- Sigma-Tau S.p.A.
- Taiho Pharmaceutical Co., Ltd.
- Terpenoid Therapeutics, Inc.
- Thar Pharmaceuticals, Inc.
For more information visit http://www.researchandmarkets.com/research/8wgmd9/bone_metastasis